ABSTRACT
BACKGROUND: Monocarboxylate transporter 8 (MCT8) is the first thyroid hormone transporter that has been linked to a human disease. Besides genetic alterations other factors might impair MCT8 activity. AIM: This study aimed at investigating whether some common drugs having a structural similarity with TH and/or whose treatment is associated with thyroid function test abnormalities, or which behave as antagonists of TH action can inhibit MCT8-mediated T3 transport. METHODS: [125I]T3 uptake and efflux were measured in COS-7 cells transiently transfected with hMCT8 before and after exposure to increasing concentrations of hydrocortisone, dexamethasone, prednisone, prednisolone, amiodarone, desethylamiodarone, dronedarone, buspirone, carbamazepine, valproic acid, and L-carnitine. The mode of inhibition was also determined. RESULTS: Dexamethasone significantly inhibited T3 uptake at 10 µM; hydrocortisone reduced T3 uptake only at high concentrations, i.e. at 500 and 1000 µM; prednisone and prednisolone were devoid of inhibitory potential. Amiodarone caused a reduction of T3 uptake by MCT8 only at the highest concentrations used (44% at 50 µM and 68% at 100 µM), and this effect was weaker than that produced by desethylamiodarone and dronedarone; buspirone resulted a potent inhibitor, reducing T3 uptake at 0.1-10 µM. L-Carnitine inhibited T3 uptake only at 500 mM and 1 M. Kinetic experiments revealed a noncompetitive mode of inhibition for all compounds. All drugs inhibiting T3 uptake did not affect T3 release. CONCLUSION: This study shows a novel effect of some common drugs, which is inhibition of T3 transport mediated by MCT8. Specifically, dexamethasone, buspirone, desethylamiodarone, and dronedarone behave as potent inhibitors of MCT8.
Subject(s)
Dexamethasone/analysis , Monocarboxylic Acid Transporters/antagonists & inhibitors , Symporters/antagonists & inhibitors , Triiodothyronine/antagonists & inhibitors , Analysis of Variance , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/therapeutic use , Anti-Arrhythmia Agents/adverse effects , Anti-Arrhythmia Agents/blood , Anti-Arrhythmia Agents/therapeutic use , Dexamethasone/blood , Dietary Supplements/adverse effects , Drug Evaluation, Preclinical/methods , Drug Evaluation, Preclinical/statistics & numerical data , Glucocorticoids/adverse effects , Glucocorticoids/blood , Glucocorticoids/therapeutic use , Humans , Monocarboxylic Acid Transporters/drug effects , Symporters/drug effects , Triiodothyronine/drug effectsABSTRACT
Stability data of toxics or drugs in gel-based or mechanical separation blood collection tubes are lacking, especially for therapeutic drug monitoring and clinical toxicology procedures. According to ISO 15189 accreditation standard, laboratories need to master the entire preanalytical process including the stability of analytes in a specific tube. Here we explored the impact of BD PST™ II and Barricor™ separator tubes on the stability of 167 therapeutic compounds and common drugs of abuse in plasma samples using LC-MS/MS. Forty drugs were significantly affected by the use of PST™ II tubes, including antidepressants (11/26), neuroleptics (9/13), cardiovascular drugs (5/26), anxiolytics and hypnotics (4/25) and some drugs of abuse (5/26). Six compounds exhibited significant reduction by the mechanical Barricor™ tubes. Ten drugs exhibited low (<85%) but non-significant recoveries due to inter-assay variability. Besides, a logPâ¯>â¯3.3 was determined as a cut-off value to predict a potential lack of stability in PST™ II gel tubes with an 86.4% sensitivity and a 61.4% specificity. As a consequence, determination of drugs with a logPâ¯>â¯3.3 should be carried out with caution in plasma samples withdrawn on PST™ II. The study showed the Barricor™ and non-gel tubes cause less drug interference and are recommended for the drugs studied.
Subject(s)
Anti-Anxiety Agents/blood , Antidepressive Agents/blood , Blood Specimen Collection , Cardiovascular Agents/blood , Hypnotics and Sedatives/blood , Illicit Drugs/blood , Blood Specimen Collection/standards , Chromatography, Liquid , Drug Evaluation, Preclinical , Drug Monitoring , Gels/chemistry , Humans , Tandem Mass SpectrometryABSTRACT
Metabolism of a novel anxiolytic GML-1 (N-benzyl-N-methyl-1-phenylpyrrolo[1,2-a]pirazin-3-carboxamide) in rat blood plasma was studied by HPLC-mass spectrometry. Three biotransformation products with the corresponding molecular ions were detected. A conclusion was made that the main pathways of GML-1 metabolism are oxidative reactions yielding hydroxylated, methylated, and demethylated metabolites.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Animals , Anti-Anxiety Agents/blood , Biotransformation , Chromatography, High Pressure Liquid , Drug Evaluation, Preclinical , Ligands , Mass Spectrometry , Oxidation-Reduction , Oxygen/chemistry , RatsABSTRACT
Vitamin C ascorbic acid) is a well-known antioxidant that is involved in anxiety, stress, depression, fatigue and mood state in humans. Studies have suggested that oxidative stress may trigger neuropsychological disorders. Antioxidants may play an important therapeutic role in combating the damage caused by oxidative stress in individuals that suffer from anxiety. In this context, it was hypothesized that oral vitamin C supplementation would reduce anxiety. However, few up to date studies have evaluated the consequences of oral vitamin C supplementation on anxiety in humans. The present study examined the effects of oral vitamin C supplements in 42 high school students, in a randomized, double-blind, placebo-controlled trial. The students were given either vitamin C (500 mg day(-1)) or placebo. Plasma concentrations of vitamin C and blood pressure were measured before the intervention and then one day after the intervention. Anxiety levels were evaluated for each student before and after 14 days following supplementation with the Beck Anxiety Inventory. Results showed that vitamin C reduced anxiety levels and led to higher plasma vitamin C concentration compared to the placebo. The mean heart rates were also significantly different between vitamin C group and placebo control group. Present study results not only provide evidence that vitamin C plays an important therapeutic role for anxiety but also point a possible use for antioxidants in the prevention or reduction of anxiety. This suggests that a diet rich in vitamin C may be an effective adjunct to medical and psychological treatment of anxiety and improve academic performance.
Subject(s)
Anti-Anxiety Agents/administration & dosage , Antioxidants/administration & dosage , Anxiety/prevention & control , Ascorbic Acid/administration & dosage , Dietary Supplements , Students/psychology , Administration, Oral , Adolescent , Adult , Anti-Anxiety Agents/blood , Anxiety/blood , Anxiety/diagnosis , Anxiety/physiopathology , Anxiety/psychology , Ascorbic Acid/blood , Blood Pressure/drug effects , Brazil , Double-Blind Method , Female , Heart Rate/drug effects , Humans , Male , Surveys and Questionnaires , Time Factors , Treatment Outcome , Young AdultABSTRACT
Herb-drug interactions are an important safety concern and this study was conducted regarding the interaction between the natural top-selling antidepressant remedy Hypericum perforatum (Hypericaceae) and conventional drugs. This study examined the influence of acute pretreatment with different extracts of Hypericum perforatum from Serbia on pentobarbital-induced sleeping time, impairment of motor coordination caused by diazepam and paracetamol pharmacokinetics in mice. Ethanolic extract, aqueous extract, infusion, tablet and capsule of Hypericum perforatum were used in this experiment. The profile of Hypericum perforatum extracts as well as paracetamol plasma concentration was determined using RP-HPLC analysis. By quantitative HPLC analysis of active principles, it has been proven that Hypericum perforatum ethanolic extract has the largest content of naphtodianthrones: hypericin (57.77 µg/mL) and pseudohypericin (155.38 µg/mL). Pretreatment with ethanolic extract of Hypericum perforatum potentiated the hypnotic effect of pentobarbital and impairment of motor coordination caused by diazepam to the greatest extent and also increased paracetamol plasma concentration in comparison to the control group. These results were in correlation with naphtodianthrone concentrations. The obtained results have shown a considerable influence of Hypericum perforatum on pentobarbital and diazepam pharmacodynamics and paracetamol pharmacokinetics.
Subject(s)
Acetaminophen/pharmacology , Diazepam/pharmacology , Herb-Drug Interactions , Hypericum/chemistry , Pentobarbital/pharmacology , Plant Extracts/pharmacology , Acetaminophen/blood , Acetaminophen/pharmacokinetics , Analgesics, Non-Narcotic/blood , Analgesics, Non-Narcotic/pharmacokinetics , Analgesics, Non-Narcotic/pharmacology , Animals , Anthracenes , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacokinetics , Anti-Anxiety Agents/pharmacology , Capsules , Diazepam/blood , Diazepam/pharmacokinetics , Female , Male , Mice , Motor Activity/drug effects , Pentobarbital/blood , Pentobarbital/pharmacokinetics , Perylene/analogs & derivatives , Perylene/analysis , Plant Extracts/blood , Plant Extracts/pharmacokinetics , Plants, Medicinal , Serbia , Solvents , TabletsABSTRACT
Pterostilbene, a natural analog of resveratrol, has diverse health-beneficial properties. However, the neurological activities of this compound are largely unexplored. Here, we report that pterostilbene shows anxiolytic-like actions by down-regulating phosphorylated levels of extracellular regulated kinases in the hippocampus of mice. Adult male mice administered pterostilbene (1-10 mg/kg, p. o.) were subjected to the elevated plus maze test. Pterostilbene manifested anxiolytic activity at 1 and 2 mg/kg doses, demonstrated by increases in % permanence time and number of open arm entries. The locomotor activity of the animals was unaffected at all doses. Western blot analysis revealed a decrease in both extracellular regulated kinase 1 and extracellular regulated kinase 2 phosphorylation in hippocampal homogenates from mice treated with 1 and 2 mg/kg pterostilbene. Moreover, pterostilbene was detected in the plasma and brains of mice following single oral administration. Anxiolytic activity was not observed at the higher doses (5 and 10 mg/kg). However, no impairment of motor function was observed either, suggesting a favorable safety index for the compound. These results suggest that pterostilbene has the potential for therapeutic drug development for anxiety disorders.
Subject(s)
Anti-Anxiety Agents/pharmacology , Hippocampus/drug effects , Mitogen-Activated Protein Kinase 3/metabolism , Stilbenes/pharmacology , Administration, Oral , Animals , Anti-Anxiety Agents/administration & dosage , Anti-Anxiety Agents/blood , Brain/drug effects , Brain/metabolism , Dose-Response Relationship, Drug , Hippocampus/metabolism , Male , Mice , Motor Activity/drug effects , Phosphorylation/drug effects , Stilbenes/administration & dosage , Stilbenes/bloodABSTRACT
The habitual consumption of marine fish is largely associated to human mental health. Fish oil is particularly rich in n-3 polyunsaturated fatty acids that are known to play a role in several neuronal and cognitive functions. In parallel, the orange-pinkish carotenoid astaxanthin (ASTA) is found in salmon and displays important antioxidant and anti-inflammatory properties. Many neuronal dysfunctions and anomalous psychotic behavior (such as anxiety, depression, etc.) have been strongly related to the higher sensitivity of cathecolaminergic brain regions to oxidative stress. Thus, the aim of this work was to study the combined effect of ASTA and fish oil on the redox status in plasma and in the monoaminergic-rich anterior forebrain region of Wistar rats with possible correlations with the anxiolytic behavior. Upon fish oil supplementation, the downregulation of superoxide dismutase and catalase activities combined to increased "free" iron content resulted in higher levels of lipid and protein oxidation in the anterior forebrain of animals. Such harmful oxidative modifications were hindered by concomitant supplementation with ASTA despite ASTA-related antioxidant protection was mainly observed in plasma. Although it is clear that ASTA properly crosses the brain-blood barrier, our data also address a possible indirect role of ASTA in restoring basal oxidative conditions in anterior forebrain of animals: by improving GSH-based antioxidant capacity of plasma. Preliminary anxiolytic tests performed in the elevated plus maze are in alignment with our biochemical observations.
Subject(s)
Anti-Anxiety Agents/administration & dosage , Antioxidants/administration & dosage , Fish Oils/administration & dosage , Oxidative Stress/drug effects , Prosencephalon/drug effects , Animals , Anti-Anxiety Agents/blood , Drug Therapy, Combination , Lipid Peroxidation/drug effects , Lipid Peroxidation/physiology , Male , Oxidative Stress/physiology , Prosencephalon/metabolism , Rats , Rats, Wistar , Xanthophylls/administration & dosage , Xanthophylls/bloodABSTRACT
The amount of afobazole and identified metabolites was measured in the urine and feces of rats after intraperitoneal and peroral administration of the drug in a dose of 25 mg/kg. Over 1 day after intraperitoneal or peroral treatment with afobazole, urine and feces contained 0.1% initial compound (from administered dose) and 42.1% metabolites.
Subject(s)
Benzimidazoles/pharmacokinetics , Benzimidazoles/urine , Feces/chemistry , Morpholines/pharmacokinetics , Morpholines/urine , Animals , Animals, Outbred Strains , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/metabolism , Anti-Anxiety Agents/pharmacokinetics , Anti-Anxiety Agents/urine , Benzimidazoles/blood , Benzimidazoles/metabolism , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Male , Morpholines/blood , Morpholines/metabolism , Rats , Time FactorsABSTRACT
The definitive anxiolytic effects of Passiflora incarnata are unknown. We studied the potential anxiolytic effects of chrysin, a Passiflora extract, and the purported modulation of the benzodiazepine receptor on the GABA(A) receptor in laboratory rats. We hypothesized that chrysin decreases anxiety via interaction with the GABA(A) receptor in laboratory rats as measured by elevated plus-maze (EPM), corticosterone, and catecholamine assays. We randomized 44 male Sprague-Dawley rats in a double-blind, placebo-controlled, between-subjects experimental design. Each animal received an intraperitoneal injection of (1) vehicle (DMSO 4%), (2) chrysin, 2 mg/kg, (3) midazolam, 1.5 mg/kg, or (4) flumazenil, 3 mg/kg and chrysin, 2 mg/kg. The EPM was used to evaluate the behavioral component of anxiolysis, and catecholamine and corticosterone assays were examined to measure the neurohormonal effects of anxiety. No statistical difference was found among groups in catecholamine and corticosterone levels. Midazolam significantly decreased anxiety compared with control and flumazenil plus chrysin groups (P <.05); there was no significant difference compared with the chrysin group. These data suggest that chrysin may have anxiolytic properties similar to midazolam but to a lesser magnitude at the 2 mg/kg dose used in this study.
Subject(s)
Anti-Anxiety Agents/therapeutic use , Anxiety/drug therapy , Flavonoids/therapeutic use , Passiflora , Plant Extracts/therapeutic use , Analysis of Variance , Animals , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacology , Behavior, Animal , Catecholamines/blood , Corticosterone/blood , Dimethyl Sulfoxide , Disease Models, Animal , Double-Blind Method , Drug Evaluation, Preclinical , Flavonoids/blood , Flavonoids/pharmacology , Flumazenil/therapeutic use , Male , Maze Learning/drug effects , Midazolam/therapeutic use , Phytotherapy/methods , Random Allocation , Rats , Rats, Sprague-Dawley , Receptors, GABA-A/drug effectsABSTRACT
In drug discovery today, drug exposure is determined in preclinical efficacy and safety studies and drug effects are related to measured concentrations rather than to the administered dose. This leads to a strong increase in the number of bioanalytical samples, demanding the development of higher throughput methods to cope with the increased workload. Here, a combined approach is described for the high-throughput preparation and liquid chromatography/tandem mass spectrometry (LC/MS/MS) analysis of drug levels in plasma samples from the preclinical efficacy and safety studies, i.e. exposure studies. Appropriate pharmacokinetic (PK) compartmental models were fitted to data from PK screening studies in the rat, which were subsequently used to simulate the expected plasma concentrations of the respective exposure studies. Information on the estimated drug concentrations was used to dilute the samples to appropriate concentration levels. A Tecan Genesis RSP liquid handling system was utilized to perform automated plasma sample preparation including serial dilution of standard solutions, dilution of plasma samples, addition of internal standard solution and precipitation with acetonitrile. This robotic sample preparation process permitted two studies of 1-96 samples each to be run simultaneously. To ensure the performance of this method the accuracy and precision for diazepam were examined. Two novel drugs were used to illustrate the suggested approach. In conclusion, our method for sample preparation of exposure samples, based on the combined use of PK simulations, a liquid handling system and a fast LC/MS/MS method, increased the throughput more than three times and minimized the errors, while maintaining the required accuracy and precision.
Subject(s)
Chromatography, Liquid/methods , Pharmaceutical Preparations/blood , Tandem Mass Spectrometry/methods , Animals , Anti-Anxiety Agents/adverse effects , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacokinetics , Computer Simulation , Diazepam/adverse effects , Diazepam/blood , Diazepam/pharmacokinetics , Drug Evaluation, Preclinical , Drug-Related Side Effects and Adverse Reactions , Male , Molecular Structure , Pharmaceutical Preparations/chemistry , Rats , Rats, Sprague-Dawley , Reference Standards , Robotics , Time Factors , Warfarin/chemistryABSTRACT
Reported adverse drug interactions with the popular herb kava have spurred investigation of the mechanisms by which kava could mediate these effects. In vivo and in vitro experiments were conducted to examine the effects of kava extract and individual kavalactones on cytochrome P450 (P450) and P-glycoprotein activity. The oral pharmacokinetics of the kavalactone, kawain (100 mg/kg), were determined in rats with and without coadministration of kava extract (256 mg/kg) to study the effect of the extract on drug disposition. Kawain was well absorbed, with >90% of the dose eliminated within 72 h, chiefly in urine. Compared with kawain alone, coadministration with kava extract caused a tripling of kawain AUC(0-8 h) and a doubling of C(max). However, a 7-day pretreatment with kava extract (256 mg /kg/day) had no effect on the pharmacokinetics of kawain administered on day 8. The 7-day pretreatment with kava extract only modestly induced hepatic P450 activities. The human hepatic microsomal P450s most strongly inhibited by kava extract (CYP2C9, CYP2C19, CYP2D6, CYP3A4) were inhibited to the same degree by a "composite" kava formulation composed of the six major kavalactones contained in the extract. K(i) values for the inhibition of CYP2C9 and CYP2C19 activities by methysticin, dihydromethysticin, and desmethoxyyangonin ranged from 5 to 10 microM. Kava extract and kavalactones (< or =9 microM) modestly stimulated P-glycoprotein ATPase activities. Taken together, the data indicate that kava can cause adverse drug reactions via inhibition of drug metabolism.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Kava/chemistry , Lactones/pharmacology , Plant Extracts/pharmacology , Pyrones/pharmacokinetics , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Adenosine Triphosphatases/metabolism , Administration, Oral , Animals , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/urine , Biological Availability , Cytochrome P-450 Enzyme Inhibitors , Cytochrome P-450 Enzyme System/metabolism , Humans , Injections, Intravenous , Lactones/pharmacokinetics , Male , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Plant Extracts/pharmacokinetics , Pyrones/administration & dosage , Pyrones/blood , Rats , Rats, Inbred F344ABSTRACT
We evaluated the pharmacokinetic interaction between a low-hyperforin St John's wort (SJW) extract and alprazolam, caffeine, tolbutamide, and digoxin. Previous reports on other SJW products had shown remarkably decreased plasma concentrations of certain co-medicated drugs, which was attributed to an inducing effect of SJW on cytochrome P-450 (CYP) and p-glycoprotein (p-gp) activity. Two randomised, placebo-controlled studies were performed with 28 healthy volunteers (age 18 - 55 years) in each study. In study A, single doses of alprazolam (1 mg; substrate of CYP3A4) and caffeine (100 mg; CYP1A2) were given on days 1 and 11. In study B, single doses of tolbutamide (500 mg, days 1 and 11; CYP2C9) and multiple doses of digoxin (0.75 mg on days -2 and -1, 0.25 mg/die on days 1 to 11; p-gp) were given. The participants received SJW (Esbericum capsules; 240 mg/die of extract, 3.5 mg hyperforin) or placebo on days 2 to 11. Blood for pharmacokinetic analysis was drawn on days 1 and 11. No statistically significant differences were found in the primary kinetic parameter, AUC0 - 24, of alprazolam, caffeine (AUC0 - 12), paraxanthine, tolbutamide, 4-hydroxytolbutamide, and digoxin between the placebo group and the SJW group at the end of the study. The SJW-induced change in AUCs was less than 12 % of the initial median AUC of the participants in studies A and B, thus clinically irrelevant. On day 11, trough concentrations were 2.0 (range 0.6 - 4.1) microg/L and 1.0 (0.2 - 3.9) microg/L for hypericin and pseudohypericin, respectively, whereas hyperforin concentrations were below the quantification limit (< 1 microg/L). Kinetics of investigated probe drugs were only marginally influenced by concomitant treatment with Esbericum capsules. This may be due in particular to the low hyperforin plasma concentration as this SJW component has been shown to activate the PXR receptor which regulates expression of CYP3A4 and p-gp. Our findings corroborate the view that reports about interactions of other SJW extracts seem not to be predictive for the product we studied.
Subject(s)
Hypericum , Phytotherapy , Plant Extracts/pharmacology , Adult , Alprazolam/blood , Alprazolam/pharmacokinetics , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/pharmacokinetics , Area Under Curve , Caffeine/blood , Caffeine/pharmacokinetics , Cardiotonic Agents/blood , Cardiotonic Agents/pharmacokinetics , Central Nervous System Stimulants/blood , Central Nervous System Stimulants/pharmacokinetics , Digoxin/blood , Digoxin/pharmacokinetics , Double-Blind Method , Drug Interactions , Female , Humans , Hypoglycemic Agents/blood , Hypoglycemic Agents/pharmacokinetics , Male , Middle Aged , Tolbutamide/blood , Tolbutamide/pharmacokinetics , Treatment OutcomeABSTRACT
A rapid and sensitive column-switching semi-micro HPLC method is described for the direct analysis of tofisopam in human serum. The sample (100 microL) was directly injected onto the precolumn (Capcell Pak MF Ph-1), where unretained proteins were eluted to waste. Tofisopam was then eluted into an enrichment column using 13% acetonitrile in 50 mM phosphate buffer (pH 7.0) containing 5 mM sodium octanesulfonate and subsequently into the analytical column using 43% acetonitrile in 0.1% phosphoric acid containing 5 mM sodium octanesulfonate. The detection limit (2 ng/mL), good precision (CV < or = 4.2%) and speed (total analysis time 24 min) of the present method were sufficient for drug monitoring. This method was successfully applied to a bioequivalence test of two commercial tofisopam tablets.
Subject(s)
Anti-Anxiety Agents/blood , Benzodiazepines , Chromatography, High Pressure Liquid/methods , Adult , Anti-Anxiety Agents/pharmacokinetics , Drug Evaluation, Preclinical , Humans , Male , Reproducibility of ResultsABSTRACT
RATIONALE: The "fear-potentiated startle" paradigm has been extensively used in animal studies, and more recently in human experimental psychopharmacology to evaluate the effects of anxiogenic and anxiety-relieving drugs. Previous human studies have shown that both the baseline and the fear-potentiated responses can be inhibited by anxiety-relieving drugs, suggesting drug activity on two different emotional states, the former reflecting a resting condition and the latter more akin to pathological anxiety. OBJECTIVES: To examine to which extent the reductions induced by a benzodiazepine on the basic and the fear-potentiated startle responses are of equal intensity, and whether or not the drug shows a predominant, i.e., selective, effect on either. METHODS: The effects of three increasing doses of the benzodiazepine alprazolam (0.25, 0.5, and 1.0 mg) were assessed on the human baseline and fear-potentiated startle responses. Twelve healthy volunteers attended the laboratory on four experimental days and received either alprazolam or placebo according to a double-blind crossover balanced design. Startle recordings were undertaken 2 h after drug intake. Fear potentiation was implemented by means of an electric-shock-anticipation experimental procedure. Additionally, subjective self-reports of sedation and anxiety and psychomotor performance were obtained at 2 and 3 h, respectively, after drug administration. RESULTS: Alprazolam dose-dependently impaired psychomotor performance and produced increases in subjective anxiolytic activity and sedation, although the latter did not reach statistical significance. Additionally, the drug reduced the magnitude of the startle response both in the absence and in the presence of a threat-related cue, although a differentially greater inhibitory effect was seen on the fear-potentiated response as the dose increased. CONCLUSIONS: Alprazolam showed a greater inhibitory effect on the fear-potentiated startle than on the baseline reflex, suggesting a more selective action of the drug on those structures mediating potentiation of the behavioral response by anxiety.
Subject(s)
Alprazolam/pharmacology , Anti-Anxiety Agents/pharmacology , Fear/psychology , Reflex, Startle/drug effects , Acoustic Stimulation , Adult , Alprazolam/blood , Anti-Anxiety Agents/blood , Blinking/drug effects , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Female , Humans , Male , Psychomotor Performance/drug effects , Reaction Time/drug effectsABSTRACT
The inhibitory effects of Angelica dahurica root extract on rat liver microsomal cytochrome P450 and drug-drug interactions were studied. The 2alpha- and 16alpha-hydroxylase activity of testosterone were most strongly inhibited, with 17.2% and 28-5% of their activity remaining, respectively, after oral administration of A. dahurica extract at a 1 g kg(-1) dose. 6beta-Hydroxylase activity was also inhibited, with 70% of its activity remaining, under the same conditions. In addition, treatment with the extract inhibited the metabolism of tolbutamide, nifedipine and bufuralol. These results showed that the extract inhibited the various isoforms of cytochrome P450 such as CYP2C, CYP3A and CYP2D1. The A. dahurica extract delayed elimination of tolbutamide after intravenous administration at a 10 mg kg(-1) dose to rats. Thus, the extract altered the liver intrinsic clearance. It had little effect, however, on the pharmacokinetic parameters of diazepam after intravenous administration at 10 mg kg(-1). Since diazepam showed high clearance, it underwent hepatic blood flow rate-limited metabolism. Therefore, the change of intrinsic clearance had little effect on hepatic clearance. However, the Cmax value after oral administration of diazepam with extract treatment was four times that with non-treatment. It was suggested that the first-pass effect was changed markedly by the extract. High-dose (1 g kg(-1)), but not low dose (0.3 g kg(-1)), administration of A. dahurica extract increased significantly the duration of rotarod disruption following intravenous administration of diazepam at 5 mg kg(-1). It was concluded that administration of A. dahurica extract has the potential to interfere with the metabolism, by liver cytochrome P450, of other drugs.
Subject(s)
Anti-Anxiety Agents/pharmacokinetics , Aryl Hydrocarbon Hydroxylases , Cytochrome P-450 Enzyme System/drug effects , Diazepam/pharmacokinetics , Drugs, Chinese Herbal/pharmacology , Hypoglycemic Agents/pharmacokinetics , Microsomes, Liver/drug effects , Tolbutamide/pharmacokinetics , Administration, Oral , Animals , Anti-Anxiety Agents/blood , Anti-Anxiety Agents/metabolism , Chromatography, High Pressure Liquid , Cytochrome P-450 Enzyme System/metabolism , Cytochrome P450 Family 2 , Diazepam/blood , Diazepam/metabolism , Dose-Response Relationship, Drug , Drug Interactions , Hypoglycemic Agents/blood , Hypoglycemic Agents/metabolism , Injections, Intravenous , Male , Microsomes, Liver/enzymology , Microsomes, Liver/metabolism , Rats , Rats, Sprague-Dawley , Steroid 16-alpha-Hydroxylase , Steroid Hydroxylases/metabolism , Tolbutamide/blood , Tolbutamide/metabolismABSTRACT
Diazepam and flunitrazepam were compared as amnesic and sedative adjuncts to local anaesthesia for diagnostic bronchoscopy in 92 patients. After local anaesthesia of the pharynx, larynx and trachea with lignocaine, atropine plus diazepam of flunitrazepam was injected i.v. The co-operation of the patients and the technical circumstances under which the bronchoscopy was performed were good in each group. None of the treatments significantly modified arterial pressure or heart rate. Two hours after the injection, flunitrazepam 0.01 mg kg-1 more frequently caused amnesia for pictures shown to the patients during the first 15 min after injection (failure to recall 42--75%, and for bronchoscopy 67%), than did diazepam 0.125 mg kg-1 (failure to recall 21--67%; bronchoscopy 38%). Double doses of the drugs caused amnesic actions similar to those of flunitrazepam 0.01 mg kg-1. When failure to recall was assessed on the following day, 29% and 5% of the patients remembered bronchoscopy after flunitrazepam 0.01 and 0.02 mg kg-1 respectively; after diazepam 0.125 and 0.25 mg kg-1 the corresponding percentages was 59% and 30% (P less than 0.05% v. fluintrazepam). The ability to stand and walk on a stright line was similar after the smaller doses of both drugs, but after the larger doses recovery was slower after flunitrazepam. Psychomotor performance was still distinctly impaired 2 h after the injection of the larger doses.